• 提示：詳情請(qǐng)下載說(shuō)明書(shū)。

• 產(chǎn)品描述： Icotinib (BPI-2009) is a potent and specific?EGFR?inhibitor with an?IC50?of 5 nM; also inhibits mutant?EGFRL858R,?EGFRL858R/T790M,?EGFRT790M?and?EGFRL861Q.

• 靶點(diǎn)： EGFR:5 nM (IC50);EGFRL858R;EGFRL858R/T790M;EGFRT790M;EGFRL861Q;EGFR

• 體內(nèi)研究：
  Icotinib exhibits potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug is well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment. Icotinib inhibits tumor growth at a rate of 25.2%, 45.6% and 51.5% in the A431 cell line groups; 3.4%, 25.9% and 31.0% in the A549 cell line groups; 49.4%, 52.6% and 67.4% in the H460 cell line groups, and 30.3%, 36.4% and 46.5% in the HCT8 cell line groups, at 30, 60 and 120 mg/kg/dose, respectively

• 參考文獻(xiàn)：
  1. Tan F, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76(2):177-82.

• 溶解性： Soluble  in  DMSO

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.555 ml	12.774 ml	25.548 ml
  5 mM	0.511 ml	2.555 ml	5.11 ml
  10 mM	0.255 ml	1.277 ml	2.555 ml
  50 mM	0.051 ml	0.255 ml	0.511 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

• 1. [IF=7.59] Jie Xu et al."Erythrocyte membrane camouflaged siRNA/chemodrugs nanoassemblies for cancer combination therapy."Biomaterials Science.2022 Oct;:

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *